Switch Therapeutics
Biotechnology
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
wilsonhillvc.comVia a fund
Global BrainVia a fund
532 portfolio companies
Insight PartnersVia a fund
812 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Switch Therapeutics appoints David M. Holtzman, M.D. to its Scientific Advisory Board and announces its first development candidate, CASi-APOE, a liver-sparing APOE RNAi therapy
Switch Therapeutics appoints David M. Holtzman, M.D. to its Scientific Advisory Board and announces its first development candidate, CASi-APOE, a liver-sparing APOE RNAi therapy - Biotech expert and renowned Alzheimer's disease researcher, David M. Holtzm
Read more
Report
Switch Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Switch Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference SOUTH SAN FRANCISCO, Calif. - June 25, 2024 - Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease util
Read more
Report
In the News: Eight biotech companies advancing in the field of siRNA
Eight biotech companies advancing the field of siRNA The post In the News: Eight biotech companies advancing in the field of siRNA appeared first on Switch Therapeutics.
Read more
Report
Switch Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
Switch Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference SOUTH SAN FRANCISCO, Calif. - February 22, 2024 - Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease utilizing its proprieta
Read more
Report
CAREERS TEMPLATE - KEEP as DRAFT
Add Your Heading Text Here Lorem ipsum dolor sit amet:consectetur adipiscing elit. Lorem ipsum dolor sit amet:consectetur adipiscing elit. Add Your Heading Text Here Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullam
Read more
Report
Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer
SWITCH THERAPEUTICS APPOINTS CHARLES ALLERSON, PH.D., AS CHIEF TECHNOLOGY OFFICER - Veteran RNA expert, oligonucleotide chemist and biotech industry expert, Charles Allerson, Ph.D., joins Switch Therapeutics from DTx Pharma to lead the acceleration of the
Read more
Report
Switch Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Switch Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif - September 6, 2023 - Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its
Read more
Report
Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors
Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors SOUTH SAN FRANCISCO, Calif - July 10, 2023 - Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi
Read more
Report
Switch Therapeutics Announces Formation of Scientific Advisory Board
Switch Therapeutics Announces Formation of Scientific Advisory Board - Inaugural Scientific Advisory Board is comprised of renowned leaders in drug discovery and development to support the advancement of Switch's novel CASi platform -- Marc Abrams, Ph.D.,
Read more
Report
Switch Therapeutics Expands Leadership Team with Key Appointments
Switch Therapeutics Expands Leadership Team with Key Appointments - Distinguished biotech leaders bring expertise to support Switch Therapeutics' ongoing growth and commitment to progressing its world class pipeline -- Craig Blanchette, Ph.D., Appointed S
Read more
Report
Show more news